Table 2.
Trends in Clinical Parameters 6 Months Before, at Baseline, and 6 Months After the Initiation of Esaxerenone
| 6 months before |
Baseline | 6 months after (on esaxerenone) |
P value | |
|---|---|---|---|---|
| Hemodynamics | ||||
| DBP (mmHg) | 81 [75–88] | 76 [71–84] | 74 [67–82] | <0.001* |
| Heart rate (beats/min) | 82 [70–89] | 75 [65–89] | 76 [69–82] | <0.001* |
| Body weight (kg) | 54.8 [48.7–65.5] | 55.0 [49.0–66.0] | 54.4 [48.7–65.6] | 0.076 |
| Medications | ||||
| β-blocker | 25 (76) | 28 (85) | 28 (85) | 1.0 |
| ACEI/ARB | 27 (82) | 27 (82) | 27 (82) | 1.0 |
| Calcium channel blocker | 10 (30) | 11 (33) | 11 (33) | 0.72 |
| Diuretics | 26 (79) | 27 (82) | 27 (82) | 0.86 |
| Laboratory data | ||||
| Hemoglobin (g/dL) | 11.2 [10.2–12.4] | 11.3 [10.1–12.7] | 11.6 [10.3–12.9] | 0.076 |
| Serum potassium (mEq/L) | 4.1 [4.0–4.5] | 4.2 [3.9–4.5] | 4.3 [4.0–4.6] | 0.80 |
| eGFR (mL/min/1.73 m2) | 53.6 [44.9–64.6] | 52.9 [42.8–62.1] | 54.8 [43.4–59.9] | 0.56 |
| Echocardiography | ||||
| LVEDd (mm) | 49 [45–53] | 51 [45–54] | 49 [43–52] | 0.001* |
| LVEF (%) | 58 [49–63] | 55 [50–63] | 61 [51–67] | 0.017* |
| E/e’ ratio | 17.2 [14.3–18.8] | 16.9 [14.1–18.4] | 16.1 [13.4–17.4] | 0.028* |
| Left atrial diameter (mm) | 42 [39–50] | 40 [37–51] | 39 [35–48] | 0.005* |
Continuous variables are presented as the median [interquartile range]; categorical variables are presented as n (%). *P<0.05. Trends were assessed using the Friedman test for the continuous variables and the Cochran Q test for the categorical variables. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; DBP, diastolic blood pressure. Other abbreviations as in Table 1.